Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464921 | 0.86 | KDM1A (0.46) | KDM1A | |
| SCHEMBL12744445 | 0.82 | CARM1 (0.46) | KDM1ACA2POLB | |
| SCHEMBL13451388 | 0.80 | KDM1A (0.43) | KDM1ACA2 | |
| SCHEMBL12744429 | 0.80 | CARM1 (0.45) | KDM1ACA2POLB | |
| SCHEMBL5720724 | 0.77 | MEN1 (0.47) | KDM1ACA2GAA | |
| SCHEMBL12744436 | 0.76 | KDM1A (0.43) | KDM1A | |
| SCHEMBL12744430 | 0.74 | KDM1A (0.48) | KDM1APOLB | |
| SCHEMBL10192208 | 0.73 | CA1 (0.44) | KDM1ACA2 | |
| SCHEMBL12744428 | 0.73 | PIK3CD (0.44) | KDM1A | |
| SCHEMBL12744446 | 0.72 | KDM1A (0.40) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910611-B2 | Therapeutic agent for restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100029625-A1 | Therapeutic Agent for Restenosis | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029625-A1 | Therapeutic Agent for Restenosis | NR1H2, NR1H3, LDLR | KDM1A 3976/4885CA2 3535/4885GAA 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.